Clinical use of misoprostol for cervical ripening before transcervical procedures in non pregnant women: a randomized comparison of vaginal and sublingual administrations


  • T. Udhayakumari Post Graduate, Department of Obstetrics & Gynaecology, Women & Children Hospital, JIPMER, Puducherry-605006
  • R. Sasirekha Associate Professor, Department of Obstetrics & Gynaecology, Women & Children Hospital, JIPMER, Puducherry-605006
  • P. Reddi Rani Professor, Department of Obstetrics & Gynaecology, Mahatma Gandhi Medical College & Research Institute, Pillayarkuppam-607402, Pondicherry


Cervical ripening, Misoprostol, Postmenopausal, Sublingual, Transcervical, Vagina


Background: Endometrial sampling techniques like endometrial biopsy, Fractional curettage, Dilatation & curettage and hysteroscopy are the common gynaecological outpatient transcervical diagnostic procedures for various clinical conditions. Complications encountered during these procedures are often due to difficulties in cervical dilatation. The incidence of these complications can be reduced if cervix is ripened before the procedures. The aim of the present study was to evaluate the efficacy of 400mcg of misoprostol administered vaginally or sublingually for cervical ripening before transcervical gynaecological diagnostic procedures in both pre and post-menopausal women.

Methods: Non pregnant pre and post-menopausal women scheduled for transcervical diagnostic procedures were assigned by computerized randomization to receive 400 mcg of misoprostol, administered either sublingually or vaginally 3-4 hours prior to the procedure. The primary outcome in this study was the pre procedural cervical width as measured by the largest number of Hegar dilators. The side effects related to misoprostol and complications associated with the procedure if any also noted.

Results: Patients were randomized to receive sublingual (50) or vaginal (50) misoprostol. The two groups were comparable in terms of age, BMI (body mass index), parity, menopausal status and indications for diagnostic procedures. The mean cervical dilatation in sublingual group was 7.28 ± 2.21 mm and it was 6.57 ± 2.24 mm in vaginal group which was statistically similar among the groups. There were no complications associated with the procedure. Side effects were also comparable among the groups.

Conclusion: Even though we found sublingual route is an effective alternate to vaginal administration of misoprostol for cervical ripening before transcervical diagnostic procedures like endometrial biopsy, fractional curettage and dilatational curettage in non pregnant pre and post-menopausal women especially when women feel uncomfortable with vaginal route. However, the optimal dose and time interval remains to be identified. It needs larger randomized control trials are required to prove clinical significance if any.



Ngai SW, Chan YM, Liu KL, Ho PC. Oral misoprostol for cervical priming in non-pregnant women. Hum Reprod.1997;12:2373-75.

Cooper K.G, Pinion SB, Bhattacharya S, Parkin DE. The effects of the gonadotrophin releasing hormone analogue (goserelin) and prostaglandin E1 (misoprostol) on cervical resistance prior to transcervical resection of the endometrium. Br J Obstet Gynecol. 1996;103:375-8.

Chocksuchat C, Cheewadhanarak S, Getpook C, Wootipoom V, Dhanavoravibul K. Misoprostol for cervical ripening in non –pregnant women: a randomized double – blind controlled trial of oral versus vaginal regimens. Hum Reprod. 2006;21:2167-70.

Darwish AM, Ahamad AM, Mohammad AM. Cervical priming prior to operative hysteroscopy: a randomized comparison of laminaria versus misoprostol. Human Reprod. 2004;19:2391-4.

Batukan C, Ozgun MT, Ozcelik B, Aygen E, Sahin Y, Turkyilmaz C. Cervical ripening before operative hysteroscopy in premenopausal women: a randomized, double – blind, placebo controlled comparison of vaginal and oral misoprostol. Fertil Steril. 2008;89:966-73.

Oppegaard KS, Nesheim BI, Istre O, Qvigstad E. Comparison of self administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design. BJOG. 2008;115:663.e1-663e9.

Atmaca R, Kafkasli A, Burak F, Tezcan TG. Priming effect of misoprostol on estrogen pretreated cervix in postmenopausal women. Tohoku J Exp Med 2005; 206:237-41.

Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002;17:332-6.

CarbonellEsteve JL, Mari JM, Valero F, Llorente M, Salvador I, Varela L, et al. Sublingual versus vaginal misoprostol (400 microg) for cervical priming in first-trimester abortion: a randomized double-blind controlled trial. Contraception 2006;74:328-333.

Fung TM, Lam MH, Wang SF, Ho LC. A randomized placebo-controlled trial of vaginal misoprostol for cervical priming before hysteroscopy in postmenopausal women. BJOG 2002;109:561-5.

Bunnasathiansri S, Herabutya Y, O-Prasertsawat P. Vaginal misoprostol for cervical priming before dilatation and curettage in postmenopausal women: a randomized controlled trial. J Obstet Gynaecol 2004;30:221-5.

Lee YY1, Kim TJ, Kang H, Choi CH, Lee JW, Kim BG, Bae DS. The use of misoprostol before hysteroscopic surgery in non-pregnant premenopausal women: a randomized comparison of sublingual, oral and vaginal administrations. Hum Reprod. 2010 Aug;25(8):1942-8.

Saav I, Aronsson A, Marions L, Stephansson O, Gemzell-Danielsson K. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized control trial. Hum Reprod. 2007;22:2647-52.

el-Rafaey H, Calder L, Wheatly DN, Templeton A. Cervical priming with prostaglandin E1 analogues, misoprostol and gemprost. Lancet. 1994;343:1207-9.

Rajabi MR, Dodge GR, Solomon S, Poole AR. Immunochemical and immune histochemical evidence of estrogen-mediated collagenolysis as a mechanism of cervical dilatation in the guinea pig at parturition. Endocrinology. 1991;128:371-8.

Barcite E, Bartusevicius A, Railate DR, Nadisauskine R. Vaginal misoprostol for cervical priming before hysteroscopy in perimenopausal and postmenopausal women. Int J Gynaecol Obstet 2005;91:141-5.

Thomas JA, Leyland N, Durand N, Windrim RC. The use of oral misoprostol as a cervical ripening agent in operative hysteroscopy: a double-blind, placebo controlled trial. Am J Obstet Gynecol. 2002;186:876-89.




How to Cite

Udhayakumari, T., Sasirekha, R., & Rani, P. R. (2017). Clinical use of misoprostol for cervical ripening before transcervical procedures in non pregnant women: a randomized comparison of vaginal and sublingual administrations. International Journal of Research in Medical Sciences, 3(1), 30–35. Retrieved from



Original Research Articles